Could a simple shot replace IV drips for some cancer patients?
NCT ID NCT04606381
First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different doses and formulations. The main goals are to check safety and how the drug moves through the body, not yet to see if it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- amivantamab (a drug that targets EGFR and cMet proteins on cancer cells)
- What this could lead to
- If successful, this could offer a more convenient way to deliver amivantamab as a shot under the skin instead of an IV infusion, potentially improving quality of life for people with certain advanced cancers.
- What could go wrong
- This is an early phase 1 study focused on safety and dosing, not on effectiveness. The drug may not work as well when given under the skin, or side effects could be different or worse. Results may not apply to all cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars Sinai Medical Center
West Hollywood, California, 90048, United States
-
Chungbuk National University Hospital
Cheongju-si, 28644, South Korea
-
Community Health Network
Indianapolis, Indiana, 46256, United States
-
Langone Health at NYC University, NYU School of Medicine
New York, New York, 10016, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Royal Marsden Hospital
Sutton, SM2 5PT, United Kingdom
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Seoul National University Bundang Hospital
Seongnam-si, 13620, South Korea
-
Severance Hospital Yonsei University Health System
Seoul, 03722, South Korea
-
The Christie Nhs Foundation Trust
Manchester, M20 4BX, United Kingdom
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?